alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 480 studies published 2005 (page 4 of 20) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of these 480 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Nature genetics 2005-12-20

We report duplication of the APP locus on chromosome 21 in five families with autosomal dominant early-onset Alzheimer disease (ADEOAD) and cerebral amyloid angiopathy (CAA). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Serum cholesterol and risk of Alzheimer disease: a community-based cohort study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2005-10-01

The data do not support an association between serum total cholesterol or high density lipoprotein in late life and subsequent risk of dementia or Alzheimer disease (AD). 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2005-06-01

APOE epsilon4 carrier status was associated with conversion to AD in older outpatients after controlling for known demographic and clinical risk factors, and APOE epsilon4 homozygosity was associated with increased risk of conversion to AD. 3 key findings →

Design: longitudinal study Participants: 57 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of psychiatry 2005-04-01

Raloxifene at a dose of 120 mg/day, but not 60 mg/day, resulted in reduced risk of cognitive impairment in postmenopausal women. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Homocysteine and folate as risk factors for dementia and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of clinical nutrition 2005-09-01

Over an average follow-up of 4 y, dementia developed in 112 subjects, including 70 who received a diagnosis of AD. 3 key findings →

Design: cross-sectional Participants: 816 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cardiovascular death in rheumatoid arthritis: a population-based study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Arthritis and rheumatism 2005-03-01

These results indicate that markers of systemic inflammation confer a statistically significant additional risk for cardiovascular death among patients with RA, even after controlling for traditional cardiovascular risk factors and comorbidities. 3 key findings →

Participants: 354 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Motor signs predict poor outcomes in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2005-05-01

A total of 533 patients with AD at early stages (mean Folstein Mini-Mental State Examination [MMSE] 21/30 at entry) were recruited and followed semiannually for up to 13.1 years (mean 3) in five University-based AD centers in the United States and European Union. 4 key findings →

Participants: 533 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2005-09-01

Because cardiovascular (CV) risk factors have been associated with declines in cognitive functions and late life dementia, CV risk factors should also be associated with brain atrophy. 4 key findings →

Participants: 1,812 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Do‐Not‐Resuscitate and Do‐Not‐Hospitalize Directives of Persons Admitted to Skilled Nursing Facilities Under the Medicare Benefit

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of the American Geriatrics Society 2005-11-08

Thirty-two percent of residents had DNR directives, whereas less than 2% had DNH directives. 5 key findings →

Design: cohort study Participants: 1,962,742 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Neuroscience 2005-08-24

Alzheimer's disease (AD) and antecedent factors associated with AD were explored using amyloid imaging and unbiased measures of longitudinal atrophy in combination with reanalysis of previous metabolic and functional studies.

Full summary, score breakdown and related studies → Original source Free full text

Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of general psychiatry 2005-11-01

Specific alleles of the DISC1 and TRAX genes on 1q42 appear to contribute to genetic risk for schizophrenia through disruptive effects on the structure and function of the prefrontal cortex, medial temporal lobe, and other brain regions. 2 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurobiology of aging 2005-08-26

The diagnosis of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) is limited because it is based on non-specific behavioral and neuroimaging findings. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMJ (Clinical research ed.) 2005-02-18

Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care. 4 key findings →

Participants: 93 Evidence: high

Full summary, score breakdown and related studies → Original source

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Current Alzheimer research 2005-07-01

Cholesterol-induced production of amyloid beta (Abeta) as a putative neurotoxin in Alzheimer's disease (AD), along with epidemiological evidence, suggests that statin drugs may provide benefit in treatment of the disorder. 5 key findings →

Participants: 98 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurobiology of aging 2005-08-08

We prospectively evaluated the diagnostic accuracy of cerebrospinal fluid (CSF)-beta-amyloid1-42 (Abeta42), -total-tau (tau) and -phosphorylated-tau181 (p-tau181) as measured by sandwich ELISAs in the clinical routine of a community state hospital to discriminate between patients with Alzheimer's disease (AD), healthy controls (HC), non-AD-dementias, a group composed of various psychiatric disorders (non-AD-dementias, mental diseases) and an age-matched random sample (RS) (total N=219). 4 key findings →

Participants: 219 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed